Trials / Recruiting
RecruitingNCT04522544
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
Detailed description
The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of Durvalumab and Tremelimumab with Y-90 SIRT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tremelimumab | 300 mg Tremelimumab C1D1 |
| DRUG | Durvalumab | 1500 mg Durvalumab C1D1 + Q4W (max. 13 cycles) |
| PROCEDURE | Y-90 SIRT | Locoregional therapy will be performed as a standard-of-care procedure |
| PROCEDURE | DEB-TACE | Locoregional therapy will be performed as a standard-of-care procedure |
Timeline
- Start date
- 2020-12-15
- Primary completion
- 2027-07-31
- Completion
- 2027-12-31
- First posted
- 2020-08-21
- Last updated
- 2026-02-18
Locations
12 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04522544. Inclusion in this directory is not an endorsement.